Skip to content

Effectiveness of Smartconsent in Improving Understanding of Informed Consent

Evaluation of the Effectiveness of Smartconsent to Improve Understanding of Informed Consent in Prostate Laser Enucleation Procedures

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04856943
Acronym
SMARTCONSENT
Enrollment
52
Registered
2021-04-23
Start date
2021-12-31
Completion date
2021-12-31
Last updated
2022-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign Prostatic Hyperplasia

Brief summary

The general objective of the study is to assess whether the new smartconsent tool improves patients' understanding of the intervention to be performed, compared to standard practice. A randomized clinical trial will be conducted in 50 patients who will undergo LASER PROSTATIC ENUCLEATION.

Detailed description

Male patients aged between 50 and 70 years, belonging to the Hospital Universitario Araba who are going to undergo PROSTATIC LASER ENUCLEATION, and who attend urology consultation between December 2019 and December 2020, and who meet the inclusion criteria and none of the exclusion criteria. Inclusion criteria: * Patients willing to receive information via tablet. * Patients who know how to and can read. Exclusion criteria: -Not applicable. Main variable: score on the Multiple choice test questionnaire (designed specifically for each type of procedure, following the recommendations proposed by Kehoe, Jerard and Fathelrahman et al. and developed on the basis of the information that an informed consent should provide (1, 2), with 4 response options and only one correct answer. An average score will be calculated for each patient. This test evaluates the comprehension of the information provided through the informed consent.

Interventions

PROCEDURESmartconsent application

Patients asigned to smartconsent group will sign informed consent through a Tablet.

OTHERControl group

Patient asigned to control group will sing the informed consent in papel, as it is performed in clinical practice

Sponsors

Bioaraba Health Research Institute
Lead SponsorNETWORK

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
50 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Patients willing to receive information via tablet. * Patients who know and can read.

Exclusion criteria

* Not applicable

Design outcomes

Primary

MeasureTime frameDescription
Score in the Multiple choice test questionnaireAt the recruitment momentSpecifically designed for each type of procedure, following the recommendations proposed by Kehoe, Jerard and Fathelrahman et al. and developed on the basis of the information to be provided in an informed consent form, with 4 response options and only one correct answer

Secondary

MeasureTime frameDescription
Satisfaction with the informed consent proccessAt the recruitment momentbased on three ad hoc designed items: Each item will be scored on a lipo Likert scale with 5 response options.
Ability to complete the informed consent formAt the recruitment momentWithout the need for additional information from the healthcare professional.
Time required to complete the informed consent process (MIN).At the recruitment momentThe Smartphone stopwatch of the researchers participating in the study will be used for this purpose
Overall satisfaction with the informed consent process,At the recruitment momentThrough a three-item test, developed ad hoc by a group of researchers to assess satisfaction in a study with similar characteristics to ours.
Score in the System Usability ScaleAt the recruitment momentIn the SMARTCONSENT group only. he average System Usability Scale score is 68. If your score is under 68, then there are probably serious problems with your website usability which you should address. If your score is above 68, then you can relax a little bit.

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026